title: Circadian rhythms of dopamine and cholecystokinin in nucleus accumbens and striatum of rats--influence on dopaminergic stimulation.
abstract: The concentrations of cholecystokinin (CCK) and dopamine (DA) were determined in the nucleus accumbens (anterior, posterior) and striatum of rats every 2 h during a period of 24 h. For both substances, a circadian rhythm was found, which was best fitted by a dominant 24-h period superimposed by the second (12 h) and fourth (6 h) harmonics. The rhythms in CCK and DA were negatively correlated because of a difference in phase position by approximately 3 h. A dominant DA peak was found in the light phase coinciding with a trough in CCK and vice versa in the dark phase. Based on these data, CCK and DA were determined in rats treated with gamma-butyrolactone (GBL; inhibitor of DA release) or thyrotropin-releasing hormone (TRH; stimulator of DA release) at 0900 h or 1300 h to study a putative time-dependency in drug effects. After GBL treatment, CCK as well as DA increased by up to 200% whereas TRH administration led to a rather complex alteration, inasmuch as CCK was increased or decreased, depending on circadian time, whereas the rhythmic pattern in DA remained relatively unaffected. Comparing the drug effects obtained at 0900 h with the response seen at 1300 h revealed significant quantitative as well as qualitative differences. The results demonstrate that the neurotransmission system investigated changed its level of activity depending on time of day. No changes were obtained that convincingly may be ascribed to colocalization of DA and CCK. It is concluded that the chronobiological data indicate a close interaction of CCK and DA in various areas of the rat brain, independent of colocalization.
authors.affiliation: Institute of Pharmacology and Toxicology, Medical Faculty (Charité), Humboldt-University of Berlin, Germany.
authors.forename: R
authors.initials: R
authors.lastname: Schade
authors.forename: K
authors.initials: K
authors.lastname: Vick
authors.forename: T
authors.initials: T
authors.lastname: Ott
authors.forename: R
authors.initials: R
authors.lastname: Sohr
authors.forename: C
authors.initials: C
authors.lastname: Pfister
authors.forename: J
authors.initials: J
authors.lastname: Bellach
authors.forename: G
authors.initials: G
authors.lastname: Golor
authors.forename: B
authors.initials: B
authors.lastname: Lemmer
mesh_terms: D015107:4-Butyrolactone / Q000494:pharmacology*; D000818:Animals; D002766:Cholecystokinin / Q000378:metabolism*; D002940:Circadian Rhythm; D003342:Corpus Striatum / Q000187:drug effects / Q000502:physiology*; D003624:Darkness; D004298:Dopamine / Q000378:metabolism*; D018757:GABA Modulators / Q000494:pharmacology*; D008027:Light; D008297:Male; D009714:Nucleus Accumbens / Q000187:drug effects / Q000502:physiology*; D009928:Organ Specificity; D051381:Rats; D017208:Rats, Wistar; D013973:Thyrotropin-Releasing Hormone / Q000494:pharmacology*; D013997:Time Factors
chemical_list: D018757:GABA Modulators; D013973:Thyrotropin-Releasing Hormone; D002766:Cholecystokinin; D015107:4-Butyrolactone; D004298:Dopamine